Why Farbe Firma is the Top Manufacturer of Etophylline + Theophylline Injection
- Maulik Sudani
- 8 hours ago
- 7 min read
Last Updated: June 13, 2026
TL;DR: Etophylline + Theophylline Injection — a sterile, clear aqueous solution combining two xanthine bronchodilators, etophylline (acepifylline) and theophylline, supplied commonly as a 2 mL ampoule (etophylline 84.7 mg + theophylline 25.3 mg per 2 mL) for slow intravenous injection — is a long-established hospital agent for the relief of acute bronchospasm in bronchial asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis and emphysema when rapid bronchodilation is required and the oral or inhaled route is not enough. Theophylline is a xanthine with a narrow therapeutic index, the combined solution must stay clear and within a tight pH window, and each ampoule must deliver an exact, sterile, particulate-free dose, so the assay of both actives, the impurity and degradation profile, pH and fill-volume control, light protection, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all matter to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Etophylline + Theophylline Injection at our Gujarat, India facility and supplies it to hospital pharmacy, respiratory, emergency and critical-care services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Xanthine bronchodilator combination — Etophylline + Theophylline Injection relaxes bronchial smooth muscle and relieves acute bronchospasm in bronchial asthma, COPD, chronic bronchitis and emphysema, delivering rapid, reliable bronchodilation by slow intravenous injection when oral or inhaled therapy is not sufficient.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, light-protected solution compounding and ampoule filling lines, dedicated dual-active assay control, plus control of the impurity profile, solution pH, fill volume, particulate and endotoxin for a narrow-therapeutic-index xanthine parenteral, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready ampoule packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Etophylline + Theophylline Injection Demands a Premium Manufacturer
Etophylline + Theophylline Injection holds a dependable, everyday place in respiratory medicine, emergency care and critical care across many markets. It is the intravenous xanthine bronchodilator that clinicians reach for when a patient in acute bronchospasm needs prompt, reliable airway relief and oral or inhaled therapy alone is not enough — in an acute exacerbation of bronchial asthma, in chronic obstructive pulmonary disease, and in chronic bronchitis and emphysema with reversible airflow obstruction. The combination pairs etophylline, a soluble xanthine derivative well suited to parenteral use, with theophylline, the classic xanthine bronchodilator; given as a slow intravenous injection from a small-volume ampoule, the two actives relax bronchial smooth muscle and improve airflow. In each of these settings the dose delivered from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, because theophylline has a narrow therapeutic index and a precise, reproducible dose is part of using it safely.
That clinical reality places real demands on the manufacturer. The product is presented as a low-volume aqueous solution combining two actives in fixed proportion, and it must remain a clear, essentially colourless solution within a tight pH window throughout shelf life. The assay of both etophylline and theophylline must be exact; the impurity and degradation profile must stay within tight limits; the pH and the deliverable volume must be controlled tightly so each ampoule gives the labelled dose of each active; the solution must be free of visible and sub-visible particulates and low in endotoxin; the product must be protected from light; and it must be sealed in an ampoule whose container-closure integrity holds across shelf life. Choosing an Etophylline + Theophylline Injection manufacturer that treats the dual-active stability-indicating assay, pH and fill-volume control, light protection, the validated sterilisation route, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Etophylline + Theophylline Injection Manufacturer Apart
A world-class manufacturer of Etophylline + Theophylline Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay that quantifies both etophylline and theophylline independently with the tight related-substance and degradation-product control by HPLC that a fixed-combination xanthine parenteral demands, a robust, validated aseptic solution-fill process — with terminal moist-heat sterilisation where the formulation and container permit it, otherwise sterile filtration and aseptic filling — that protects the assay, the pH and the clarity of the solution, and tender-ready dossier support for a hospital-formulary product procured through pharmacy and ministry-of-health channels. It starts with the actives — pharmacopoeial-grade etophylline and theophylline sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend both the assay and the dose. The bulk solution is compounded in water-for-injection at the controlled pH that keeps both xanthines stable and fully in solution, sterile-filtered through 0.22 µm membrane, and filled into ampoules under light-protected ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where qualified, otherwise full aseptic processing — locked in the master batch record. Filled ampoules are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of both etophylline and theophylline by validated HPLC, the related-substance profile, solution pH, deliverable volume, visible and sub-visible particulate matter, and endotoxin is held well within limits so the injection is safe for intravenous administration. Because the combination is light-sensitive, the compounding, holding and filling steps and the finished pack are all protected from light.
Quality Systems Behind Every Etophylline + Theophylline Injection
Every Farbe Firma Etophylline + Theophylline Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of both etophylline and theophylline against pharmacopoeial reference standards, control of related substances and degradation products by HPLC, solution pH, deliverable (fill) volume, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, light-protected (low-actinic) compounding and filling areas, validated ampoule-filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because theophylline has a narrow therapeutic index and the assay, pH, clarity and particulate burden of the combined solution drive both efficacy and safety, we treat the dual-active stability-indicating HPLC assay, the solution pH, the deliverable volume and the related-substance profile as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected from light through its ampoule labelling and secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Etophylline + Theophylline Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad small-volume parenteral portfolio across respiratory, critical-care, anti-infective and supportive-care categories. For Etophylline + Theophylline Injection specifically, we supply the 2 mL single-dose ampoule (etophylline 84.7 mg + theophylline 25.3 mg per 2 mL) of sterile solution under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the dual-active stability-indicating-assay, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data for both actives, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Etophylline + Theophylline Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, light-protected artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing for both xanthines, dual-active stability-indicating assay development, related-substance and degradation control, pH and solubility design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose control, light-protection strategy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a narrow-therapeutic-index fixed-combination xanthine parenteral where assay accuracy, pH and particulate control directly govern both effect and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Etophylline + Theophylline Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Etophylline + Theophylline Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, light-protected solution compounding and ampoule filling lines, validated sterilisation, qualified water-for-injection systems, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Etophylline + Theophylline Injection do you supply?
Our standard presentation is the 2 mL single-dose ampoule containing etophylline 84.7 mg and theophylline 25.3 mg, for slow intravenous injection. Custom strengths, fill configurations, ampoule or vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
Why is the assay control so important for a theophylline-containing injection?
Theophylline has a narrow therapeutic index, so the dose delivered from each ampoule must be exact and reproducible. Farbe Firma uses a validated, stability-indicating HPLC method that quantifies both etophylline and theophylline independently, controls related substances and degradation products, and confirms pH, deliverable volume and clarity at release so each ampoule delivers the labelled dose of each active.
Can Farbe Firma support country-specific registrations for Etophylline + Theophylline Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Etophylline + Theophylline Injection contract manufacturing?
MOQs vary by strength, ampoule size, sterilisation route, label complexity and dossier requirements. For our small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments